Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02000622




Registration number
NCT02000622
Ethics application status
Date submitted
18/11/2013
Date registered
4/12/2013

Titles & IDs
Public title
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Scientific title
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Secondary ID [1] 0 0
2013-005137-20
Secondary ID [2] 0 0
D0819C00003
Universal Trial Number (UTN)
Trial acronym
OlympiAD
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer Metastatic 0 0
BRCA 1 Gene Mutation 0 0
BRCA 2 Gene Mutation 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Olaparib
Treatment: Drugs - Physician's choice chemotherapy

Experimental: Olaparib - Olaparib tablet 300mg bd po

Active comparator: Physician's choice chemotherapy - Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21


Treatment: Drugs: Olaparib
Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.

Treatment: Drugs: Physician's choice chemotherapy
Investigators will declare one of the following regimens:

* Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days
* Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days
* Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)
Timepoint [1] 0 0
Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
Secondary outcome [1] 0 0
Time to Second Progression or Death (PFS2)
Timepoint [1] 0 0
Second progression status reviewed every 8 weeks following the first objective radiological progression as per investigator assessment. Assessed up to a maximum of 30 months.
Secondary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks. Assessed up to a maximum of 30 months.
Secondary outcome [3] 0 0
Objective Response Rate (ORR) Using Blinded Independent Central Review (BICR) Data Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)
Timepoint [3] 0 0
Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
Secondary outcome [4] 0 0
Adjusted Mean Change in Global Health Status/Quality of Life (QoL) Score From the European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30)
Timepoint [4] 0 0
EORTC QLQ-C30 assessments performed at baseline then every ~6 weeks until objective radiological disease progression. Assessed up to a maximum of 30 months.
Secondary outcome [5] 0 0
Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) in Patients Confirmed as Myriad CDx gBRCAm
Timepoint [5] 0 0
Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
Secondary outcome [6] 0 0
Overall Survival (OS) at Final OS
Timepoint [6] 0 0
Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks. Assessed up to a maximum of 40 months.
Secondary outcome [7] 0 0
Overall Survival (OS) at Extended OS
Timepoint [7] 0 0
Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.

Eligibility
Key inclusion criteria
* Germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious.
* Histologically or cytologically confirmed breast cancer with evidence of metastatic disease.
* Prior therapy with an anthracycline and a taxane in either an adjuvant or metastatic setting.
* Prior platinum allowed as long as no breast cancer progression occurred on treatment or if given in adjuvant/neoadjuvant setting at least 12 months from last dose to study entry elapsed.
* ER/PR breast cancer positive patients must have received and progressed on at least one endocrine therapy (adjuvant or metastatic), or have disease that the treating physician believes to be inappropriate for endocrine therapy.
* ECOG performance status 0-1.
* Adequate bone marrow, kidney and liver function.
Minimum age
18 Years
Maximum age
99 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior treatment with PARP inhibitor.
* Patients with HER2 positive disease.
* More than 2 prior lines of chemotherapy for metastatic breast cancer.
* Untreated and/or uncontrolled brain metastases.
* Prior malignancy unless curatively treated and disease-free for > 5 years prior to study entry. Prior adequately treated non-melanoma skin cancer, in situ cancer of the cervix, DCIS or stage I grade 1 endometrial cancer allowed.
* Known HIV (Human Immunodeficiency Virus) infection.
* Pregnant or breast-feeding women.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/03/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/12/2024
Actual
Sample size
Target
Accrual to date
Final
302
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Mississippi
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
New Hampshire
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Vermont
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Plovdiv
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Sofia
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Varna
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Vratza
Country [27] 0 0
China
State/province [27] 0 0
Beijing
Country [28] 0 0
China
State/province [28] 0 0
Changchun
Country [29] 0 0
China
State/province [29] 0 0
Changsha
Country [30] 0 0
China
State/province [30] 0 0
Chengdu
Country [31] 0 0
China
State/province [31] 0 0
Dalian
Country [32] 0 0
China
State/province [32] 0 0
Guangzhou
Country [33] 0 0
China
State/province [33] 0 0
Hangzhou
Country [34] 0 0
China
State/province [34] 0 0
Harbin
Country [35] 0 0
China
State/province [35] 0 0
Nanjing
Country [36] 0 0
China
State/province [36] 0 0
Shanghai
Country [37] 0 0
China
State/province [37] 0 0
Shenyang
Country [38] 0 0
China
State/province [38] 0 0
Tianjin
Country [39] 0 0
Czechia
State/province [39] 0 0
Brno
Country [40] 0 0
Czechia
State/province [40] 0 0
Olomouc
Country [41] 0 0
Czechia
State/province [41] 0 0
Praha 2
Country [42] 0 0
France
State/province [42] 0 0
Caen Cedex
Country [43] 0 0
France
State/province [43] 0 0
Montpellier
Country [44] 0 0
France
State/province [44] 0 0
Rouen
Country [45] 0 0
France
State/province [45] 0 0
Strasbourg Cedex
Country [46] 0 0
France
State/province [46] 0 0
Villejuif
Country [47] 0 0
Hungary
State/province [47] 0 0
Budapest
Country [48] 0 0
Hungary
State/province [48] 0 0
Nyíregyháza
Country [49] 0 0
Hungary
State/province [49] 0 0
Veszprém
Country [50] 0 0
Italy
State/province [50] 0 0
Bologna
Country [51] 0 0
Italy
State/province [51] 0 0
Napoli
Country [52] 0 0
Italy
State/province [52] 0 0
Padova
Country [53] 0 0
Italy
State/province [53] 0 0
Roma
Country [54] 0 0
Italy
State/province [54] 0 0
Rozzano
Country [55] 0 0
Japan
State/province [55] 0 0
Chuo-ku
Country [56] 0 0
Japan
State/province [56] 0 0
Fukuoka-shi
Country [57] 0 0
Japan
State/province [57] 0 0
Kagoshima-shi
Country [58] 0 0
Japan
State/province [58] 0 0
Nagoya-shi
Country [59] 0 0
Japan
State/province [59] 0 0
Osaka-city
Country [60] 0 0
Japan
State/province [60] 0 0
Sapporo-shi
Country [61] 0 0
Japan
State/province [61] 0 0
Shinagawa-ku
Country [62] 0 0
Japan
State/province [62] 0 0
Suita-city
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Cheongju-si
Country [64] 0 0
Korea, Republic of
State/province [64] 0 0
Daegu
Country [65] 0 0
Korea, Republic of
State/province [65] 0 0
Incheon
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Seongnam-si
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Seoul
Country [68] 0 0
Mexico
State/province [68] 0 0
Estado de México
Country [69] 0 0
Mexico
State/province [69] 0 0
Merida
Country [70] 0 0
Mexico
State/province [70] 0 0
Mexico
Country [71] 0 0
Mexico
State/province [71] 0 0
Mérida
Country [72] 0 0
Mexico
State/province [72] 0 0
San Juan del Rio
Country [73] 0 0
Peru
State/province [73] 0 0
Cusco
Country [74] 0 0
Peru
State/province [74] 0 0
Lima
Country [75] 0 0
Peru
State/province [75] 0 0
San Borja
Country [76] 0 0
Poland
State/province [76] 0 0
Elblag
Country [77] 0 0
Poland
State/province [77] 0 0
Gdansk
Country [78] 0 0
Poland
State/province [78] 0 0
Grzepnica
Country [79] 0 0
Poland
State/province [79] 0 0
Tarnobrzeg
Country [80] 0 0
Poland
State/province [80] 0 0
Warszawa
Country [81] 0 0
Poland
State/province [81] 0 0
Lódz
Country [82] 0 0
Romania
State/province [82] 0 0
Bucharest
Country [83] 0 0
Romania
State/province [83] 0 0
Bucuresti
Country [84] 0 0
Romania
State/province [84] 0 0
Cluj Napoca
Country [85] 0 0
Romania
State/province [85] 0 0
Cluj-Napoca
Country [86] 0 0
Russian Federation
State/province [86] 0 0
Arkhangelsk
Country [87] 0 0
Russian Federation
State/province [87] 0 0
Ivanovo
Country [88] 0 0
Russian Federation
State/province [88] 0 0
Moscow
Country [89] 0 0
Russian Federation
State/province [89] 0 0
Omsk
Country [90] 0 0
Russian Federation
State/province [90] 0 0
Saint Petersburg
Country [91] 0 0
Russian Federation
State/province [91] 0 0
Saransk
Country [92] 0 0
Russian Federation
State/province [92] 0 0
St-Petersburg
Country [93] 0 0
Russian Federation
State/province [93] 0 0
St.Petersburg
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Yaroslavl
Country [95] 0 0
Spain
State/province [95] 0 0
Barcelona
Country [96] 0 0
Spain
State/province [96] 0 0
Córdoba
Country [97] 0 0
Spain
State/province [97] 0 0
Granada
Country [98] 0 0
Spain
State/province [98] 0 0
Madrid
Country [99] 0 0
Spain
State/province [99] 0 0
Majadahonda
Country [100] 0 0
Spain
State/province [100] 0 0
Oviedo
Country [101] 0 0
Spain
State/province [101] 0 0
Sevilla
Country [102] 0 0
Spain
State/province [102] 0 0
Valencia
Country [103] 0 0
Spain
State/province [103] 0 0
Zaragoza
Country [104] 0 0
Switzerland
State/province [104] 0 0
Bern
Country [105] 0 0
Switzerland
State/province [105] 0 0
Lausanne
Country [106] 0 0
Switzerland
State/province [106] 0 0
Zürich
Country [107] 0 0
Taiwan
State/province [107] 0 0
Kaohsiung
Country [108] 0 0
Taiwan
State/province [108] 0 0
Taichung
Country [109] 0 0
Taiwan
State/province [109] 0 0
Taipei
Country [110] 0 0
Taiwan
State/province [110] 0 0
Taoyuan
Country [111] 0 0
Turkey
State/province [111] 0 0
Adana
Country [112] 0 0
Turkey
State/province [112] 0 0
Ankara
Country [113] 0 0
Turkey
State/province [113] 0 0
Edirne
Country [114] 0 0
Turkey
State/province [114] 0 0
Gaziantep
Country [115] 0 0
Turkey
State/province [115] 0 0
Istanbul
Country [116] 0 0
Turkey
State/province [116] 0 0
Izmir
Country [117] 0 0
Turkey
State/province [117] 0 0
Kayseri
Country [118] 0 0
Turkey
State/province [118] 0 0
Konya
Country [119] 0 0
Turkey
State/province [119] 0 0
Mersin
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Aberdeen
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Colchester
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Coventry
Country [123] 0 0
United Kingdom
State/province [123] 0 0
London
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Manchester
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Plymouth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Myriad Genetic Laboratories, Inc.
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/industry
Name [2] 0 0
Merck Sharp & Dohme LLC
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Mark Robson, MD
Address 0 0
Memorial Sloan-Kettering Cancer Center, New York
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting document/s available: Study protocol, Statistical analysis plan (SAP)
When will data be available (start and end dates)?
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Available to whom?
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://astrazenecagroup-dt.pharmacm.com/DT/Home


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT02000622